Direct renin inhibition is a new means for blocking the renin–angiotensin system at the rate-limiting step of the cascade of events triggered by renin release—the interaction of renin with its ...

Circulating renin–angiotensin system (RAS) activation is maintained after renal function has deteriorated. The activation of the intrarenal RAS plays a critical role in the pathophysiology of chronic ...

The argument was elegant in its simplicity. Patients with high levels of renin had a vasoconstriction type of hypertension that was driven primarily by the actions of the renin-angiotensin system on ...

Three large randomized trials tested a simple idea: if one blood-pressure drug that blocks the renin-angiotensin system ...

Introduction Physiology of the Renin-Angiotensin-Aldosterone System and Its Pathophysiologic Role in Some Forms of Hypertension Renin in the Selection of Antihypertensive Drug Therapy Renin as a ...

New Orleans, La. (March 27, 2007) -- A combination of two medicines that act against the effects of the enzyme renin are more effective in lowering blood pressure than either of the medicines alone, ...

Diabetic nephropathy is the leading cause of end-stage renal disease in developed countries. We evaluated the renoprotective effects of dual blockade of the renin−angiotensin−aldosterone system by ...

High blood pressure, also called hypertension, is one of the most common health problems in the world. Millions of people ...

Initial evidence of the existence of renin, which is an angiotensinogenase enzyme secreted by the kidney, was presented to the medical community more than 100 years ago. Nevertheless, the significance ...

THE role of the kidney in the regulation of blood pressure through the mediation of renin was first suggested by the classic experiments of Goldblatt. 1 Although there was considerable initial ...

Cost-effectiveness of NALIRIFOX compared to other first-line treatments for metastatic pancreatic cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This ...

a Multivariate model adjusting for cancer therapy including antimetabolites, Vascular endothelial growth factors inhibitors, taxanes, tyrosine kinase inhibitors, monoclonal antibodies, vinca alkaloids ...